Artax Biopharma To Present Phase 2a Psoriasis Data On AX-158 At 2025 SID Annual Meeting

Artax Biopharma is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases. The firm has announced that its Phase 2a clinical trial evaluating AX-158, a novel Nck pathway modulator, in patients with psoriasis will be featured as a late-breaking oral presentation at the upcoming Society for Investigative Dermatology (SID) Annual Meeting. The event is scheduled to take place from May 7–10, 2025, in San Diego, California.

Dr. Chris VanDeusen, Chief Scientific Officer, will present “AX-158 Proof-of-Mechanism Safety Study: Evaluating a Novel T cell Receptor (TCR) Signal Modulator in Patients with Mild-to-Moderate Plaque Psoriasis (NCT05725057),” final abstract ID number LB1150, on May 9, 2025, in the Concurrent Mini-symposium. The abstract will present key findings from the study, highlighting the safety profile, efficacy outcomes, and biomarker data associated with AX-158.